Nimbus Therapeutics and Charles River Laboratories International, Inc. have entered a multi-year strategic partnership aimed at advancing new programs in immunology, metabolic disorders and oncology from the discovery phase through to Investigational New Drug (IND) submission.
 
The companies will work to advance programs through discovery and preclinical development, leveraging Charles River’s initial hit identification through discovery optimization, including medicinal chemistry and pharmacology, and into safety testing and IND submission. Charles River is eligible to receive potential milestone payments. Nimbus will apply its computational chemistry expertise throughout the drug discovery and development process.
 
“We expect that our portfolio of discovery and safety assessment expertise, together with Nimbus’ impressive track record in using computational chemistry to accelerate drug discovery, will result in additional speed and scale to their future pipeline,” said James Foster, chairman, president and chief executive officer of Charles River Labs.
 
Don Nicholson, Ph.D., chief executive officer of Nimbus, said, “Charles River’s broad experience in discovery research across multiple therapeutic areas, as well as background in safety assessment, makes them a highly valued contributor to Nimbus’ drug discovery efforts. We’re looking forward to furthering our collaboration with Charles River as we work together to progress the most promising targets through discovery and preclinical development.”